Ib1-IIa2期子宫颈癌术后辅助治疗方法比较的队列研究

杨 春燕, 禹 莲香, 龙 爱娥
怀化市肿瘤医院妇瘤科

摘要

目的:通过子宫颈鳞状细胞癌术后队列研究,探讨Ib1-IIa2期子宫颈鳞状细胞癌术后不同辅助治疗方法的临床治疗效果以及不良反应,指导其术后辅助治疗方案的选择｡方法:选取2018年1月至2019年1月120例经广泛性子宫切除+盆腔淋巴结清扫术术后具有中危因素的Ib1-IIa2期子宫颈鳞状细胞癌患者,将其随机分为化疗组(60例)与放疗组(60例),比较两组在治疗过程中以及治疗结束后12月患者不良反应的发生率,治疗12月后的复发率及转移率､无瘤生存率｡结果:两组在治疗过程中放疗组消化道反应､骨髓抑制､肝功能异常低于化疗组(P<0.05),随访12个月转移及复发率､无瘤生存率两组无明显差异(P>0.05),化疗组下肢水肿发生率较放疗组低,差异有显著性(P<0.05)｡结论:单纯化疗和同步放化疗疗效相当,对于既往认为具有中危因素术后需补充放射治疗的Ib1—IIa2期子宫颈鳞状细胞癌患者可以选择单纯化学治疗｡

关键词

Ib1-IIa2期;宫颈鳞状细胞癌;术后辅助治疗;队列研究

参考

[1]BrayF,FerlayJ,SoerjomataramI,eta1.Globalcancerstatistics2018:GLOBOCANestimatesofincidenceandmortalityworldwidefor36cancersin185countries.CACancerJClin.2018;68(6):394-424.[2]周文毓,惠宁,张建平.多种新辅助治疗方法对ⅠB2~ⅡA期宫颈癌患者的疗效及预后影响[J].实用妇产科杂志,2015,31(4):303-307.ZHOUWY,HUIN,ZHANGJP.ComparisionofClinicalEfficacyandOutcomesofMultipleNeoadjuvantTreatmentsforPatientswithStageⅠB2-ⅡACervicalCancer.JournalofPracticalObstetricsandGynecology,2015,31(4):303-307.[3]吉维,冉立,常建英,等.不同治疗方式对术后伴中危因素Ⅰ-ⅡA期宫颈癌预后影响[J].中华放射肿瘤学杂,2019,28(5):358-363.JIW,RanLChJIANY,eta1.EffectofdifferenttherapeuticmethodsonsurvivalofstageⅠ-ⅡAcervicalcancerpatientscomplicatedwithpostoperativeintermediateriskfactors[J].ChineseJournalofRadiationOncology,2019,28(5):358-363.[4]钱冰,王晓芳.50例术后复发ⅡA期宫颈癌患者的临床特征及危险因素分析[J].癌症进展,2018,16(15):1926-1929.QIANB,WANGXF.Clinicalcharacteristicsandriskfactorsof50patientswithrecurrentstageIIAcervicalcancerafteroperation.OncologyProgress,2018,16(15):1926-1929.[5]高楠,李大鹏,盛修贵,等.早期宫颈癌术后伴高危复发因素患者不同治疗方式疗效和并发症的观察[J].肿瘤学杂志,2017,23(4):312-316.GAON,LIDP,SHENGXG.TheEffectivenessandComplicationsofDifferentTreatmentModalitiesAfterSurgeryforEarly-StageHighRiskCervicalCarcinoma[J].JournalofChineseOncology,2017,23(4):312-316.[6]杜俊瑶,张新,李联崑,等.同步放化疗与单纯放疗治疗中晚期宫颈癌疗效及毒性反应比较研究[J].中国实用妇科与产科杂志,2015,31(3):256-260.DUJY,ZHANGX,LILK.Retrospectivestudyofchemoradiotherapycomparedwithradiothrepyaloneforcervicalcancer[J].ChineseJournalofPracticalGynecologyandObstetrics,2015,31(3):256-260.[7]TakekumaM,KasamatsuY,KadoN,etal.Adjuvantchemotherapyversusconcurrentchemoradiotherapyforhighriskcervicalcancerafterradicalhysterectomyandsystematiclymphadenectomy[J].IntJClinOncol,2016,21(4):741-747.[8]HosakaM,WatariH,TakedaM,eta1.Treatmentofcervicalcancerwithadjuvantchemotherapyversusadjuvantradiotherapyafterradicalhysterectomyandsystematiclymphadenectomy[J].J0bstetGynaecolRes,[9]MATSUOK,SHIMADAM,YOKOTAH,etal.Effectivenessofadjuvantsystemicchemotherapyforintermediate-riskstageIBcervicalcancer[J].Oncotarget,2017,8(63)[10]唐秋,屠晔,陈建红.同步放化疗治疗早期宫颈癌术后中危患者的疗效分析[J].中华肿瘤杂志.2018,40(6):462-466.TangQ,TuYQ,ChenJH.Therapeuticeffectofsynchronousradiotherapyandchemotherapyonpatientswithearlycervicalcancerafteroperation[J].ChinJ462-466.[11]齐文彩,吴鸣.宫颈癌经典治疗的现状和思考[J].癌症进展,2019,17(8):893-896.QIWC,WUM,Currentsituationandthinkingofclassicaltreatmentofcervicalcancer[J].OncologyProgress,2019,17(8):893-896.[12]JungPS,KimDY,LeeSW,etal.ClinicalroleofadjuvantchemotherapyafterradicalhysterectomyforFIGOstageIB-IIAcervicalcancer:comparisonwithadjuvantRT/CCRTusinginverse-probability-oftreatmentweighting[J].PLoSOne,2015,10(7):e0132298.[13]温宏武,黄卫平,廖秦平,等.不同辅助治疗方法对1b-IIa期子宫颈癌术后有危险因素患者预后的影响[J].中华妇产科杂志,2013,42(12):920-924.WENHW,HUANGWP,LIAOQP,etal.ResultsofdifferentpostoperativeadjuvanttherapiesforstageⅠb-Ⅱacervicalcarcinomawithriskfactors[J].ChineseJournalofObstetricsandGynecology,2013,42(12):920-924.[14]TakekumaM,KasamatsuY,KadoN,etal.Adjuvantchemotherapyversusconcurretchemoradiotherapyforhigh-riskcervicalcanceraftterradicalhysterectomyandsyste-maticlym-phadenectomy[J].IntJClinOncol,2016,21(4):741-747.